Selective effects of the anticancer drug Yondelis (ET-743) on cell-cycle promoters

Molecular Pharmacology

Volumn 68, Issue 5, 2005, Pages 1496-1503

  Minuzzo, Mario ^a   Ceribelli, Michele ^a   Pitarque Martì, Marià ^a   Borrelli, Serena ^a   Erba, Eugenio ^b   DiSilvio, Alberto ^a   D'Incalci, Maurizio ^b   Mantovani, Roberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B2; CYCLIN DEPENDENT KINASE 2; CYTOCHROME P450 3A4; DNA; HISTONE; HISTONE ACETYLTRANSFERASE; METALLOTHIONEIN; NUCLEAR FACTOR; NUCLEAR FACTOR Y; TRABECTEDIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ARTICLE; ASSAY; CELL CYCLE; CHROMATIN; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; DRUG SELECTIVITY; DRUG TARGETING; GENE TARGETING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CCAAT-BINDING FACTOR; CELL CYCLE; DIOXOLES; DNA; ISOQUINOLINES; MICE; NIH 3T3 CELLS; PROMOTER REGIONS (GENETICS); TETRAHYDROISOQUINOLINES; TRANSCRIPTION, GENETIC;

EID: 27544493942     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.013615     Document Type: Article

References (42)

1. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
2. Bolognese F, Wasner M, Lange-zu Dohna C, Gurtner A, Ronchi A, Muller H, Manni I, Mossner J, Piaggio G, Mantovani R et al. (1999) The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 18:1845-1853.
3. Bonfanti M, Caretti G, LaValle E, Sousa Faro JMF, Faircloth G, Mantovani R, and D'Incalci M (1999) Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 14:179-186.
4. Botz J, Zerfass-Thome K, Spitkovsky D, Delius H, Vogt B, Eilers M, Hatzigeorgiou A, and Jansen-Durr P (1996) Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol Cell Biol 16:3401-3409.
5. Caretti G, Salsi V, Vecchi C, Imbriano C, and Mantovani R (2003) Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J Biol Chem 278:30435-30440.
6. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth G, and d'Incalci M (2001) Unique pattern of Yondelis activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92:583-588.
7. D'Incalci M and Jimeno J (2003) Preclinical and clinical results with the natural marine product Yondelis. Expert Opin Investig Drugs 12:1843-1853.
8. Donald S, Verschoyle RD, Edwards R, Judah DJ, Davies R, Riley J, Dinsdale D, Lopez Lazaro L, Smith AG, Gant TW, et al. (2002) Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (Yondelis) in the female rat. Cancer Res 62:4256-4262.
9. Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth G, and d'Incalci M (2001) Ecteinascidin-743 (Yondelis), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37:97-105.
10. Erba E, Cavallaro E, Damia G, Mantovani R, Di Silvio A, Di Francesco AM, Riccardi R, Cuevas C, Faircloth GT, and D'Incalci M (2005) The unique biological features of the marine product Yondelis (ET-743, Trabectedin) are shared by its analog PM00128, which lacks the C-ring. Oncol Res 14:579-587.
11. Friedman D, Hu Z, Kolb EA, Gorfajn B, and Scotto KW (2002) Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 62:3377-3381.
12. Fry CJ, Slansky JE, and Farnham PJ (1997) Position-dependent transcriptional regulation of the murine dihydrofolate reductase promoter by the E2F transactivation domain. Mol Cell Biol 17:1966-1976.
13. Gajate C, An F, and Mollinedo F (2002) Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 277:41580-41589.
14. Henglein B, Chenivesse X, Wang J, Eick D, and Brechot C (1994) Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci USA 91:5490-5494.
15. 2/M promoters. Mol Cell Biol 25:3737-3751.
16. Jin S, Gorfajn B, Faircloth G, and Scotto K (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97:6775-6779.
17. Ku DH, Wen SC, Engelhard A, Nicolaides NC, Lipson KE, Marino TA, and Calabretta B (1993) c-myb transactivates cdc2 expression via Myb binding sites in the 5′-flanking region of the human cdc2 gene. J Biol Chem 268:2255-2259.
18. Kurabayashi M, Dutta S, Jeyaseelan R, and Kedes L (1995) Doxorubicin-induced Id2A gene transcription is targeted at an activating transcription factor/cyclic AMP response element motif through novel mechanisms involving protein kinases distinct from protein kinase C and protein kinase A. Mol Cell Biol 15:6386-6397.
19. Lange-zu Dohna C, Brandeis M, Berr F, Mossner J, and Engeland K (2000) A CDE/CHR tandem element regulates cell cycle-dependent repression of cyclin B2 transcription. FEBS Lett 484:77-81.
20. Lee L-F, Haskill S, Mukaida N, Matsushima K, and Ting JP-Y (1997) Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter. Mol Cell Biol 17:5097-5105.
21. Levine M and Tjian R (2003) Transcription regulation and animal diversity. Nature (Lond) 424:147-151.
22. Li Q, Hu N, Daggett MA, Chu WA, Bittel D, Johnson JA, and Andrews GK (1998) Participation of upstream stimulator factor (USF) in cadmium-induction of the mouse metallothionein I gene. Nucleic Acids Res 26:5182-5189.
23. Louneva N, Saitta B, Herrick DJ, and Jimenez SA (2003) Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743. J Biol Chem 278:40400-40407.
24. Mantovani R (1999) The molecular biology of the CCAAT-bonding factor NF-Y. Gene 239:15-27.
25. Marchini S, Marrazzo E, Bonomi R, Chiorino G, Zaffaroni M, Weissbach L, Hornicek FJ, Broggini M, Faircloth GT, and D'Incalci M (2005) Molecular characterization of two human cancer cell lines selected in vitro for chemotherapeutic drug resistance to ET-743. Eur J Cancer 41:323-333.
26. Martinez EJ, Corey EJ, and Owa T (2001) Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 8:1151-1160.
27. Martinez EJ, Owa T, Schreiber SL, and Corey EJ (1999) Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. Proc Natl Acad Sci USA 96:3496-3501.
28. Minuzzo M, Marchini S, Broggini M, Faircloth G, d'Incalci M, and Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97:6780-6784.
29. Moore BM, Seaman FC, and Hurley LH (1997) NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 119:5475-5476.
30. Moos PJ and Fitzpatrick FA (1998) Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95:3896-3901.
31. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, and Kohn KW (1996) Sequence and structure-selective alkylation of guanine N2 in the minor groove by Ecteinascidin 743, a potent antitumour compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309.
32. Ronchi A, Bellorini M, Mongelli N, and Mantovani R (1995) CCAAT-box binding protein NF-Y (CBF, CP1) recognizes the minor groove and distorts DNA. Nucleic Acids Res 23:4565-4572.
33. Scotto KW (2002) ET-743: more than an innovative mechanism of action. Anticancer Drugs 13/1:S3-S6.
34. Sorensen P and Wintersberger E (1999) Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promoter. J Biol Chem 274:30943-30949.
35. Spitkovsky A, Schulze A, Boye B, and Jansen-Durr P (1997) Down-regulation of cyclin A gene expression upon genotoxic stress correlates with reduced binding of free E2F to the promoter. Cell Growth Differ 8:699-710.
36. Synold TW, Dussault I, and Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 8:584-590.
37. Takahashi Y, Rayman JB, and Dynlacht BD (2000) Analysis of promoter binding by the E2F and RB families in vivo: distinct E2F proteins mediate activation and repression. Genes Dev 14:804-816.
38. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, et al. (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 8:961-966.
39. Wang W, Dong L, Saville B, and Safe S (1999) Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol 13:1373-1387.
40. Wells J, Boyd KE, Fry CJ, Bartley SM, and Farnham PJ (2000) Target gene specificity of the E2F and pocket protein family members in living cells. Mol Cell Biol 20:5797-5807.
41. Zewail-Foote M and Hurley LH (1999a) Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42:2493-2497.
42. Zewail-Foote M and Hurley LH (1999b) Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level. Anticancer Drugs Design 14:1-9.